Ascendis Pharma A/S reports results for the quarter ended September 30 - Earnings Summary

Ascendis Pharma A/S

15/11/2024 14:05

* Ascendis Pharma A/S  ASND.OQ  reported a quarterly
adjusted loss
of €1.72​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of €-2.88.  The mean expectation of thirteen analysts for the
quarter was for a loss of €1.74 per share. Wall Street expected
results to range from $-2.14 to €-1.23 per share.
    * Revenue rose 20.4% to $57.83 million from a year ago;
analysts
expected €82.36 million. 
    * Ascendis Pharma A/S's reported EPS for the quarter was a
loss of
€1.72​.
    * The company reported a quarterly loss of €99.2 million.
    * Ascendis Pharma A/S shares had fallen by 16.8% this
quarter and
lost 1.3% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 44.4%
in the last three months.​ 
    * In the last 30 days, four analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma
A/S is $191.00 
This summary was machine generated from LSEG data November 15 at
02:04 p.m. UTC. ​All figures in euros unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.74          -1.72          Beat
 Jun. 30 2024      -1.38          -1.91          Missed
 Mar. 31 2024      -1.50          -2.30          Missed
 Dec. 31 2023      -2.03          -1.54          Beat